Core Viewpoint - Amarin is in a precarious position due to restructuring efforts to cut costs and facing generic competition for its only drug, Vascepa, which may lead investors to prefer larger pharmaceutical companies [1][5]. Financial Position - Amarin has a strong financial position with no long-term debt, a cash balance of nearly $135 million, and short-term investments worth just under $168 million, allowing it to sustain operations for years [2]. - In 2025, Amarin reported product sales of nearly $183 million, and a restructuring effort is expected to generate positive free cash flow in 2026 [4]. Revenue Challenges - The company's sales have declined from $285 million two years ago, primarily due to generic competition affecting Vascepa, leading to concerns about the sustainability of its financial situation [5]. - The ongoing revenue decline poses a significant risk, as Amarin may need to further reduce spending to maintain its financial health [7]. Industry Comparison - The pharmaceutical sector typically experiences cycles, but Amarin's reliance on a single drug limits its operational strength compared to larger companies with diversified portfolios [8]. - Companies like Pfizer, despite facing challenges, have the ability to pivot and leverage a broader drug portfolio, positioning them more favorably in the market [9].

Company Overview - Amarin's shares have increased by approximately 22% over the past year, but its future prospects remain uncertain due to the presence of generics in the market for its sole product, Vascepa [6] - In fiscal 2025, Amarin reported a total revenue of $213.6 million, reflecting a year-over-year decrease of 6.5% [6] Financial Performance - Amarin's net loss per share improved to $0.09 in 2025, compared to a loss of $0.20 in 2024, indicating progress in cost-cutting measures despite declining sales [7] Legal and Strategic Developments - Amarin is currently involved in a legal dispute with Hikma Pharmaceuticals regarding the marketing of a generic version of Vascepa, with the case now at the U.S. Supreme Court [8] - The company has partnered with Recordati Industria Chimica e Farmaceutica to commercialize Vascepa in 59 countries, receiving an upfront payment of $25 million and potential earnings of up to $150 million based on milestones [9]

Core Insights - Amarin Corporation (AMRN) reported adjusted earnings of 1 cent per share for Q4 2025, surpassing the Zacks Consensus Estimate of a loss of $1.27, and improved from an adjusted loss of 2 cents per share in the same quarter last year [1][6] - Total revenues for Q4 were $49.2 million, falling short of the Zacks Consensus Estimate of $51 million, and representing a 21% decline from the previous year due to lower sales volume and pricing issues [2][6] - The company's stock declined by 9% following the earnings announcement, although shares have increased by 22.5% over the past year compared to the industry growth of 19.2% [2] Revenue Breakdown - Net product revenues from Vascepa in Q4 were $46.5 million, down 23% year over year, and missed the Zacks Consensus Estimate of $48.7 million [4][6] - U.S. product revenues from Vascepa decreased by 7% year over year to $41.1 million, attributed to lower net selling prices [4] - European product revenues from Vazkepa totaled $2.3 million, a 42% decrease from the previous year, due to the transition to a partnered model with Recordati [7] - Revenues from the Rest of the World were $3.1 million, down 74% year over year, while licensing and royalty revenues increased by 20% to $2.7 million [7] Cost Management and Cash Flow - Selling, general and administrative expenses declined by 46% year over year to $20.1 million, reflecting restructuring and cost-optimization efforts [8] - Research and development expenses remained consistent at $5.4 million compared to the prior year [8] - The company achieved positive cash flow in Q4 2025, earlier than previously expected in 2026 [9] Full-Year Performance - For the full year 2025, Amarin reported total revenues of $213.6 million, a decrease of 6.5% year over year [10] - Adjusted net earnings for the full year were 4 cents per share, compared to a net loss of 7 cents per share in 2024 [10] - The company incurred $36.2 million in restructuring charges for the year and anticipates total charges of $37 million to $40 million, with remaining costs expected in early 2026 [10] Strategic Developments - In 2025, Amarin entered into a long-term license and supply agreement with Recordati to commercialize Vazkepa across 59 European countries [11] - The company launched a global restructuring program aimed at achieving $70 million in annual cost savings, with $31 million already realized [11] - Management believes that the fully partnered ex-U.S. business model will help reduce costs and maintain positive cash flow in 2026 [12]

Core Viewpoint - The U.S. Supreme Court's decision to hear a patent dispute involving Amarin Pharma's cardiovascular drug Vascepa may significantly impact generic drug manufacturers and the "skinny label" strategy [1] Group 1: Patent Dispute - The case centers around Amarin Pharma's Vascepa, which is a cardiovascular drug [1] - The outcome of this dispute could set a precedent affecting the generic drug market [1] Group 2: Implications for Generic Drug Makers - The ruling may influence how generic drug makers approach the development and marketing of their products [1] - The "skinny label" strategy, which allows generics to avoid patent infringement by omitting certain indications, could be affected by the court's decision [1]

Core Viewpoint - Edding Group Company Limited is set to reverse merge with Jiahe Biotech-B (06998.HK) through a share swap, marking Hong Kong's first reverse merger of an unprofitable biotech company under the 18A rule [3][5]. Group 1: Company Overview - Edding Group is a comprehensive biopharmaceutical company that has established a competitive portfolio of innovative drugs through acquisitions and licensing agreements with multinational pharmaceutical companies [5]. - The company has successfully launched multiple innovative drugs in China over its 20 years of operation, demonstrating strong clinical development and management capabilities [5]. - Edding's product portfolio includes five main products, three of which are original research products and two are innovative products, all of which have been commercialized [5][6]. Group 2: Financial Performance - Edding's revenue for the years 2022, 2023, 2024, and the first half of 2025 was RMB 2.073 billion, RMB 2.304 billion, RMB 2.546 billion, and RMB 1.136 billion respectively, with corresponding net profits of RMB 306 million, RMB 308 million, RMB 389 million, and RMB 115 million [17][18]. - The gross profit margin for the years 2022 to 2025 remained relatively stable, with gross profits of RMB 1.368 billion (66.0%), RMB 1.506 billion (65.4%), RMB 1.716 billion (67.4%), and RMB 760 million (66.9%) [18]. Group 3: Shareholder Structure - Prior to the merger, the controlling shareholder, Mr. Ni Xin, held 45.19% of the voting rights through various entities [10][11]. - Post-merger, Mr. Ni is expected to become the controlling shareholder of Edding Jiahe, with an estimated holding of approximately 37.39% [10][11]. Group 4: Management Team - The expanded board of directors will consist of seven members, including two executive directors, two non-executive directors, and three independent directors, effective upon completion of the merger [14][15]. - Key executives include Dr. Guo Feng as CEO and Dr. Han Shuhua as Chief Scientific Officer [15].

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Post Hearing Information Pack, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Post Hearing Information Pack. Post Hearing Information Pack of GENOR BIOPHARMA HOLDINGS LIMITED 嘉和生物藥業 (開 曼 )控股有限公司 (the "Company") (Incorpora ...

香港聯合交易所有限公司及證券及期貨事務監察委員會對本聆訊後資料集的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並表明概不就因本聆訊後資料集全部或任何部分內容而產生或依賴該等內容而 引致的任何損失承擔任何責任。 a a a a a a a a a a a a a a a a GENOR BIOPHARMA HOLDINGS LIMITED 嘉和生物藥業（開曼）控股有限公司 （「本公司」） （於開曼群島註冊成立的有限公司） （股份代號：6998） 的聆訊後資料集 警告 閣下如已將名下之嘉和生物藥業（開曼）控股有限公司股份全部售出或轉讓，應立即將本通函連同隨附之代表委任表格，送交買主或承讓 人或經手買賣或轉讓之銀行、股票經紀或其他代理，以便轉交買主或承讓人。 本通函僅供參考，並不構成收購、購買或認購本公司證券的邀請或要約。 a a a a a a a a a a a a a a a a GENOR BIOPHARMA HOLDINGS LIMITED 嘉和生物藥業（開曼）控股有限公司 本聆訊後資料集乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的 要求而刊發，僅用作向香港 ...

香港聯合交易所有限公司及證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並表明概不就因本申請版本全部或任何部分內容而產生或依賴該等內容而引致的任 何損失承擔任何責任。 a a a a a a a a a a a a a a a a GENOR BIOPHARMA HOLDINGS LIMITED 嘉和生物藥業（開曼）控股有限公司 （「本公司」） （於開曼群島註冊成立的有限公司） （股份代號：6998） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作向香港公眾人士提供資料。 本申請版本為草擬本，其所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即表示 閣下 知悉、接納並向本公司、其聯席保薦人或顧問表示同意： (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的。投資者不應根據本文件所 載資料作出投資決定； (b) 在聯交所網站刊發本文件或其任何補充、修訂或更換附頁，並不會引致本公司、其聯席保薦人或顧 問任何須進行本公司反向收購交易（「反向收購交易」）的責任。 ...

The publication of this Application Proof is required by The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and the Securities and Futures Commission (the "Commission") solely for the purpose of providing information to the public in Hong Kong. This Application Proof is in draft form. The information contained in it is incomplete and is subject to change which can be material. By viewing this document, you acknowledge, accept and agree with the Company, its joint sponsors or advisers that: GENOR ...

Core Insights - Amarin Corporation (AMRN) reported adjusted earnings of 1 cent per share for Q3 2025, missing the Zacks Consensus Estimate of 8 cents per share, compared to an adjusted loss of 5 cents per share in the same quarter last year [1][7] - Total revenues for Q3 were $49.7 million, exceeding the Zacks Consensus Estimate of $43 million, and representing a 17% increase year-over-year due to higher product sales in the U.S. [2][7] Financial Performance - The reported earnings excluded stock-based compensation and restructuring expenses; including these, the company incurred a loss of 2 cents per share in Q3 2025, an improvement from a loss of 6 cents per share in the prior year [2] - Net product revenues from Vascepa, the company's sole marketed drug, were $48.6 million, a 16% year-over-year increase, with U.S. product revenues totaling $40.9 million, surging 34% from the previous year [4][7] - Revenues from the European market for Vazkepa totaled $4.1 million, down 5% year-over-year, attributed to the transition to a fully partnered model with Recordati [5] - Revenues from the rest of the world were $3.6 million, down 48% year-over-year, while licensing and royalty revenues increased by 149% to $1.1 million [8] Cost Management - Selling, general, and administrative expenses decreased by 47% year-over-year to $19.7 million, reflecting the impact of recent restructuring and cost optimization efforts [8] - Research and development expenses totaled $4.2 million, down 7% year-over-year [9] Strategic Developments - Amarin signed a long-term license and supply agreement with Recordati to commercialize Vazkepa across 59 countries in the EU, which is expected to accelerate growth in the European market [10][11] - The company initiated a global restructuring expected to deliver approximately $70 million in cost savings over the next year [10] Market Reaction - Following the earnings announcement, Amarin's shares fell by 11.3% on October 29, although the stock has rallied 73.3% year-to-date compared to the industry's increase of 10.8% [3]